目的 分析吉瑞替尼相關不良反應的臨床特征,為臨床安全合理用藥提供參考。方法 檢索中國知網(wǎng)、維普、萬方、PubMed、Embase數(shù)據(jù)庫關于吉瑞替尼相關不良反應的個案報道或病例分析,并進行統(tǒng)計分析。結(jié)果 共納入文獻13篇,共涉及患者20例,其中男性7例(35%),女性13例(65%);年齡分布以50歲以上患者居多(14例,70%);原患疾病主要為復發(fā)性或難治性急性髓系白血病(19例,95%);大部分不良反應發(fā)生在2個月以內(nèi)(16例,80%);不良反應主要累及神經(jīng)系統(tǒng)(25%),胃腸系統(tǒng)(17.5%)和皮膚系統(tǒng)(17.5%),其中嚴重急性腎損傷、免疫相關性腸炎和顱內(nèi)出血是新發(fā)不良反應。大部分患者對癥治療后均好轉(zhuǎn),2例患者因顱內(nèi)出血后出現(xiàn)并發(fā)癥而死亡。結(jié)論 臨床應加強對吉瑞替尼相關不良反應的防范,保障患者用藥安全。

Objective To analyze the clinical characteristics of adverse drug reaction induced by gilteritinib, so as to provide reference for clinical safe and rational drug use. Methods Searching the case reports or studies in CNKI, VIP, Wanfang, PubMed, and Embase, the adverse drug reaction cases related to gilteritinib were statistical analyzed. Results A total of 13 literatures involving 20 patients were enrolled in our study, including 7 males (35%) and 13 females (65%). The majority of patients were over 50 years old (14 cases, 70%) and the primary disease was relapsed or refractory acute myeloid leukemia (19 cases, 95%). Most adverse drug reaction occurred within 2 months (16 cases, 80%), mainly involving nervous system (25%), gastrointestinal system (17.5%) and skin system (17.5%). Severe acute kidney injury, immune-related enteritis, and intracranial hemorrhage were the new adverse drug reaction. Most patients were improved after receiving symptomatic treatment, but 2 patients died of complications after intracranial hemorrhage. Conclusion The prevention of adverse drug reaction related to gilteritinib should be strengthened, so as to ensure the safety of patients.

R973;R979.1